Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects
Status:
COMPLETED
Trial end date:
2023-08-25
Target enrollment:
Participant gender:
Summary
Primary ObjectiveTo compare the pharmacokinetic profiles between meloxicam nanocrystal injection (strength: 1 mL: 30 mg, Yangtze River Pharmaceutical Group Co., Ltd.) and the originator meloxicam nanocrystal injection (trade name: ANJESO, strength: 1 mL: 30 mg, Baudax Bio Inc.) in healthy volunteers.
Secondary ObjectiveTo observe the safety and tolerability of meloxicam nanocrystal injection and ANJESO in healthy volunteers.